Work

Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation

Year: 2025

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2025.2518135

Authors: Lili Su, Xiangyu Zhang, Mengrong Li, Ying Li, Dong Wang

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Wu Jieping Medical Foundation

Award: G2467670205

OpenAlex ID: W4411150182

FWCI: 0.956

Cites: 28

Cited by: 2

Related to: 10